Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2025)

Vivos Therapeutics has reported Capital Expenditures over the past 6 years, most recently at $1.5 million for Q4 2025.

  • Quarterly Capital Expenditures rose 827.88% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 312.15% year-over-year, with the annual reading at $2.3 million for FY2025, 312.15% up from the prior year.
  • Capital Expenditures was $1.5 million for Q4 2025 at Vivos Therapeutics, up from -$83000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $1.5 million in Q4 2025 and troughed at -$1.9 million in Q4 2021.
  • The 5-year median for Capital Expenditures is $165000.0 (2024), against an average of $234882.4.
  • The largest YoY upside for Capital Expenditures was 16701.23% in 2021 against a maximum downside of 8174.3% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at -$1.9 million in 2021, then skyrocketed by 110.5% to $200000.0 in 2022, then crashed by 75.0% to $50000.0 in 2023, then surged by 230.0% to $165000.0 in 2024, then skyrocketed by 827.88% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Capital Expenditures are $1.5 million (Q4 2025), -$83000.0 (Q3 2025), and $771000.0 (Q2 2025).